FDA officials apparently think that doctors aren’t smart enough to understand the labels on the medications they prescribe.

The agency recently released draft guidance for how the pharmaceutical industry should label “biosimilars,” a new class of medicines. These guidelines state that biosimilars’ labels should leave out critical information in order to avoid causing “confusion” among doctors.